Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Patient Education

Podcast: How New Gene Therapies for SCD May Impact Women’s Fertility

key information

source: Foundation for Women & Girls with Blood Disorders

year: 2024

summary/abstract:

As we closed 2023, the Food and Drug Administration (FDA) approved two gene therapies to treat sickle cell disease (SCD). These potential curative therapies include CASGEVY™ (exagamglogene autotemcel [exa-cel]) from Vertex Pharmaceuticals Incorporated and CRISPER Therapeutics, and LYFGENIATM from bluebirdbio. While there is a lot of excitement for these advances, the impacts of these therapies are not currently known. Like with many therapies, the impact on women and their future fertility are among the unknowns and are areas of concern for individuals living with sickle cell disease and their healthcare providers.

Please join 7-2-1 for this special edition episode, How New Gene Therapies for SCD May Impact Women’s Fertility, with WGSCD LAN Chair, Dr. Alecia Nero and special guest, Dr. Kelly Acharya, a Reproductive Endocrinologist, and Infertility Specialist with Duke Health. Together, they discuss the areas of concern for women and girls living with SCD and consider what the future may hold for those who are able to receive these life-changing treatments so that they may stay informed in the decision-making process.

read more

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close